The social stigma surrounding an anal cancer diagnosis has traditionally prevented open
discussions about this disease. However, as recent treatment options and an increasing rate …

The multitude of multi-omics data generated cost-effectively using advanced high-
throughput technologies has imposed challenging domain for research in Artificial …

Background No standard therapies beyond first line are established for advanced squamous
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …

Although rare, the rate of squamous cell carcinoma of the anus (SCCA) is rising globally.
Most patients present with nonmetastatic disease and are curable with appropriate …

Anal cancer is a rare cancer that accounts for about 2% of all gastrointestinal tract
malignancies. Among anal cancer, squamous cell cancer is the most common malignancy …

Simple Summary While anti-PD1 antibodies have demonstrated efficacy in some patients
with metastatic anal cancer, these agents have no proven benefit for those with localized …

Genome sequencing of cancer has fundamentally advanced our understanding of the
underlying biology of this disease, and more recently has provided approaches to …

For decades metastatic squamous cell carcinoma of the anus (SCCA) has been considered
a rare disease with very limited treatment options and a dismal prognosis. Prior to 2017, no …

Background Rectal cancers represent 35% of colorectal cancers; 90% are
adenocarcinomas, while squamous cell carcinoma accounts for 0.3% of them. Given its …

The management of anal squamous cell carcinoma (ASCC) has yet to experience the
transformative impact of precision medicine. Conducting genomic analyses may uncover …